Janssen Pharmaceutical Inc.
Titusville
New Jersey
United States
615 articles about Janssen Pharmaceutical Inc.
-
Yet another drug for Alzheimer’s has been tossed in the trash. AstraZeneca and Eli Lilly announced they have abandoned two late-stage clinical trials of lanabecestat for Alzheimer’s disease.
-
New Late-Breaking Data on the Use of Type 2 Diabetes Treatment INVOKANA® (canagliflozin) in the Real World Will Be Presented at the American Diabetes Association's 78th Annual Scientific Sessions
6/8/2018
Featured Data Includes Findings From OBSERVE-4D - the Largest Real-World Study to Evaluate the Risk of Lower Extremity Amputation and Hospitalization for Heart Failure
-
Evolving Treatment Strategies in Multiple Myeloma: Janssen's Darzalex Leads a Host of Novel Agents in Redefining Treatment Strategies and Approaches
6/7/2018
A new independent report from Spherix Global Insights examines the emerging trends and unveils near term shifts that are anticipated in this field which is experiencing its "golden age" of drug development.
-
BioSpace takes a look at some notable programs that have been shuttered so far this year.
-
The Janssen Pharmaceutical Companies, part of Johnson & Johnson, presented two-year data from its IM-UNITI trial of Stelara (ustekinumab) in Crohn’s disease.
-
TREMFYA® (guselkumab) Study Indicating The Significance Of Inhibiting IL-23 Pathway In Adults With Psoriatic Arthritis Published In The Lancet
6/4/2018
The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced results from a Phase 2 study that were published in The Lancet demonstrating positive results for TREMFYA® (guselkumab).
-
With the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ongoing, there are hundreds of newsworthy stories. Here is a few of our top picks so far.
-
Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer
6/3/2018
The Janssen Pharmaceutical Companies of Johnson & Johnson announced findings from a Phase 2 study that showed treatment with erdafitinib.
-
IMBRUVICA® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström's Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin's Lymphoma
6/1/2018
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from a pre-planned interim analysis of the Phase 3 iNNOVATE (PCYC-1127) study evaluating the investigational use of IMBRUVICA® (ibrutinib) in combination with rituximab in relapsed/refractory and treatment-naïve patients with Waldenström's macroglobulinemia (WM).
-
Long-Term Phase 3 Study Shows Esketamine Nasal Spray Plus an Oral Antidepressant Delayed Time to Relapse in Patients with Treatment-Resistant Depression
5/31/2018
A separate Phase 3 study provides evidence that esketamine was generally well tolerated with no new safety signals with up to 52 weeks of dosing for patients with treatment-resistant depression
-
Within the next six years, the multiple myeloma market is projected to be $37.5 billion – an incredible growth of $30 billion since 2015, when the market was valued at about $7.5 billion.
-
Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma
5/30/2018
Planned Start of Clinical Program and Clearance of U.S. Food and Drug Administration Investigational New Drug Application Reflect Progress in Strategic Partnership with Legend Biotech
-
New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation
5/24/2018
The Janssen Pharmaceutical Companiesof Johnson & Johnson today announced new real-world data that showed frail patients with non-valvular atrial fibrillation (NVAF) experienced significantly fewer strokes and systemic emboli when treated with XARELTO® (rivaroxaban) over a two-year period compared to those taking warfarin.
-
Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1
5/21/2018
Dolutegravir/rilpivirine, the result of a collaboration with ViiV Healthcare, offers a complete daily treatment regimen for virologically suppressed adults living with HIV-1 in a single-pill
-
On May 19 every year the people who are afflicted with IBD disorders unite across the globe to raise awareness of the disease and urge governments and healthcare systems to continue to focus on the development of necessary treatments.
-
Johnson & Johnson’s Janssen division has decided to end its trials of atabacestat, a BACE inhibitor, for Alzheimer’s disease.
-
Janssen Announces DARZALEX® (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible
5/8/2018
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved DARZALEX® (daratumumab) in combination with VELCADE® (bortezomib).
-
GenomeDx Biosciences Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Decipher® Classifier and Decipher GRID® for Drug Development
5/8/2018
GenomeDx Biosciences announced a research collaboration with Janssen Pharmaceuticals.
-
Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder.
-
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.